Related by context. All words. (Click for frequent words.) 84 evaluable 83 patients evaluable 79 RECIST criteria 72 evaluable subjects 72 RECIST 72 CR CRu 72 partial remissions 71 remission CR 71 tumor shrinkage 70 cytogenetic response 69 complete remissions 69 Partial Responses 69 complete cytogenetic 69 dose cohorts 69 RECIST Response Evaluation Criteria 69 mg/m2 dose 68 CR nPR 68 dosing cohorts 68 chlorambucil 68 Response Evaluation Criteria 68 heavily pretreated patients 68 mg BID 68 mg kg dose 68 free survival PFS 67 mcg kg 67 prospectively defined 67 undetectable HCV RNA 66 FOLFOX 66 heavily pretreated 66 CRp 66 tumor regression 66 median PFS 66 Solid Tumors RECIST 66 dose cohort 66 cytogenetic responses 66 CCyR 65 PRECiSE 65 recurrent GBM 65 carboplatin paclitaxel 65 nodular partial response 65 dose escalation 65 FOLPI 65 platinum refractory 65 progression TTP 65 HBeAg positive patients 65 treatment naive genotype 65 plus dexamethasone 64 lymphocytosis 64 neoadjuvant chemotherapy 64 neoadjuvant 64 splenectomized patients 64 mRCC 64 stage IIIB 64 placebo dexamethasone 64 HCV genotype 64 hematologic 64 rapid virologic response 64 relapsed MM 64 histologically confirmed 64 dose limiting toxicities 64 biochemical relapse 64 dasatinib 64 achieved ACR# 64 #mg QD [002] 64 mCRC patients 63 secondary efficacy endpoints 63 dose escalation phase 63 timepoint 63 RRMS patients 63 HBeAg seroconversion 63 HCV SPRINT 63 oblimersen 63 null responders 63 chemoradiotherapy 63 FOLFOX4 63 Partial Response 63 mcg albinterferon alfa 2b 63 low dose cytarabine 63 liver metastases 63 refractory CLL 63 treatment naïve genotype 63 ACR# response 63 CIMZIA TM 63 mg QD 63 undetectable HBV DNA 63 glufosfamide 63 metastatic RCC 63 locoregional disease 63 follicular lymphomas 63 locoregional 63 viral kinetics 63 Secondary endpoints 63 metastatic renal cell carcinoma 63 IMGN# 63 chemoradiation 63 Complete Response CR 63 BRIM2 63 mg/m2 63 metastatic GIST 63 prior chemotherapy regimens 63 MCyR 63 achieved CCyR 63 tumor recurrence 63 primary endpoint 63 Fludara 63 CLL SLL 63 imatinib 63 RGT arm 63 HGS ETR1 62 crizotinib PF # 62 #mg/m# [001] 62 galiximab 62 bortezomib 62 pomalidomide 62 Kaplan Meier analysis 62 DLTs 62 telaprevir dosed 62 mg ustekinumab 62 achieved sustained virologic 62 CRu 62 comparator arm 62 pegylated interferon alfa 2b 62 relapsed refractory multiple myeloma 62 Solid Tumors criteria 62 nab paclitaxel 62 HBeAg positive 62 locoregional recurrence 62 Flu Cy 62 KRAS mutations occur 62 recurrent glioblastoma multiforme 62 underwent resection 62 systemic ALCL 62 secondary endpoint 62 elotuzumab 62 leukemia AML 62 HCV RESPOND 2 62 Phase Ib clinical 62 iniparib BSI 62 pCR 62 achieved sustained virological 62 complete cytogenetic response 62 seroconversion 62 gefitinib 62 Phase 1b 62 relapsed refractory 61 Free Survival PFS 61 virologic failure 61 null responder HCV 61 dose escalation study 61 peginterferon alfa 2a 61 distant metastasis 61 Amrubicin 61 mg dose 61 lung metastases 61 IV NSCLC 61 Kaplan Meier estimate 61 metastatic CRC 61 multicenter Phase 61 vandetanib 61 refractory AML 61 neoadjuvant treatment 61 dose escalation trial 61 ZACTIMA 61 ACTEMRA TM 61 HER2 positive metastatic breast 61 randomized Phase 61 melphalan prednisone 61 mcg BID 61 endoscopic remission 61 XIENCE V PROMUS Stent 61 nonresponders 61 APTIVUS r 61 achieved PASI 61 randomized 61 HBeAg negative patients 61 #mg dose [002] 61 low dose dexamethasone 61 ongoing Phase 1b 61 DAPT 61 docetaxel 61 #mg BID [001] 61 sustained virological response 61 NSCLC 61 TELCYTA 61 plus ribavirin 61 timepoints 61 virologic 61 FOLFIRI 61 bendamustine 61 decitabine 61 plus methotrexate 61 monotherapy 61 Dacogen injection 61 mapatumumab 61 μg dose 61 TMC# r 61 sustained virologic response 61 intermittent dosing 61 MabCampath 61 Phase 2a trial 61 n = 61 infliximab 61 multicenter randomized controlled 61 rindopepimut 61 DAS# remission 61 mg/m2/day 61 randomized #:# 61 HCV RNA 61 SVR# 61 neoadjuvant therapy 61 refractory NSCLC 61 serum HCV RNA 61 randomized Phase 2b 61 peginterferon alfa 2b 61 T#I mutation 61 EURIDIS 61 HCV infected 61 XELOX 61 neurologic progression 61 recurrent NSCLC 61 gemcitabine 60 SUTENT 60 % CI #.#-#.# [003] 60 ACTEMRA 60 adalimumab 60 desvenlafaxine succinate 60 plasma uric acid 60 EOquin TM 60 BRIM3 60 axitinib 60 PREZISTA r 60 randomized Phase III 60 placebo controlled clinical 60 sunitinib 60 atazanavir ritonavir 60 Phase 2b study 60 underwent surgical resection 60 peginterferon 60 response pCR 60 definite stent thrombosis 60 HCV genotype 1 60 CAMMS# 60 Median PFS 60 rituximab 60 virologic response 60 VELCADE melphalan 60 DAS# CRP 60 viral kinetic 60 placebo controlled Phase 60 Median progression 60 dose escalation clinical 60 events SAEs 60 remission induction 60 PASI scores 60 virologic response EVR 60 pancreatic adenocarcinoma 60 Solid Tumors 60 ribavirin RBV 60 BCIRG 60 visceral metastases 60 azacitidine 60 ug dose 60 CIMZIA ™ 60 IIIB NSCLC 60 rALLy trial 60 log# reduction 60 tumor progression TTP 60 squamous histology 60 dacarbazine DTIC 60 certolizumab 60 bortezomib refractory 60 pertuzumab 60 biochemical recurrence 60 primary efficacy endpoint 60 zalutumumab 60 phase IIa clinical 60 nilotinib 60 ascending dose 60 Phase 1b clinical 60 Secondary endpoints include 60 elacytarabine 60 preoperative chemotherapy 60 LEXIVA r 60 Folfox 60 docetaxel chemotherapy 60 GOUT 60 plus prednisone 60 mycophenolate mofetil 60 oral ridaforolimus 60 EBMT criteria 60 PEG IFN 60 Bezielle 60 dosage regimens 60 lumiliximab 60 valopicitabine 60 clodronate 60 mg administered orally 60 postoperative chemotherapy 60 estramustine 60 unresectable 60 REYATAZ r arm 60 Pegasys plus Copegus 60 antiangiogenic therapy 60 mcg dose 60 posaconazole 59 metastatic HRPC 59 Median survival 59 alemtuzumab treated 59 indolent NHL 59 mcg QD 59 Traficet EN 59 GVAX 59 relapsed multiple myeloma 59 plus gemcitabine 59 annualized relapse 59 mitoxantrone 59 temsirolimus 59 imatinib therapy 59 placebo controlled clinical trials 59 ACR# responses 59 #mg/m# [002] 59 HSCT 59 liver transplant recipients 59 gemcitabine carboplatin 59 follicular NHL 59 ribavirin therapy 59 Phase Ib 59 8mg/kg 59 pT2 59 teriflunomide 59 Aptivus ® 59 q#d 59 VGPR 59 Phase Ib II 59 pharmacokinetics PK 59 histologically proven 59 previously untreated follicular 59 clinically meaningful improvement 59 cEVR 59 ABCSG 59 pegylated interferon alpha 59 Phase Ib study 59 APPRAISE 59 genotypic resistance 59 phase IIb clinical 59 neratinib 59 oral FTY# 59 IFN α 59 relapsed MCL 59 4mg/kg 59 papillary renal cell carcinoma 59 peg IFN 59 limiting toxicity 59 phase Ib 59 distant metastases 59 febrile neutropenia 59 vicriviroc 59 phase IIb study 59 FluCAM arm 59 cabazitaxel 59 Doxil ® 59 Peg IFN 59 TORISEL 59 unresectable stage 59 dosing cohort 59 NMIBC 59 etanercept 59 follicular lymphoma 59 lamivudine refractory patients 59 alicaforsen enema 59 satraplatin Phase 59 biliary tract cancer 59 standard chemotherapy regimen 59 DMARD 59 R# #mg BID 59 IIa trial 59 virologic breakthrough 59 brain metastases 59 CIMZIA TM certolizumab pegol 59 nucleoside naive 59 composite endpoint 59 hepatitis C genotype 59 ABSORB trial 59 HBeAg negative 59 detectable HCV RNA 59 methotrexate monotherapy 59 tumor regressions 59 KRAS status 59 tanespimycin 59 #mg BID [002] 59 5-FU/LV 59 lopinavir r arm 59 LUX Lung 59 randomized Phase IIb 59 ascending doses 59 octreotide LAR 58 OncoVEX GM CSF 58 huN# DM1 58 ZYBRESTAT 58 evaluating REVLIMID 58 secondary efficacy endpoint 58 FluCAM 58 Randomized Phase 58 pegylated liposomal doxorubicin 58 serum phosphorus 58 virological failure 58 forodesine 58 ACR Pedi 58 TAXUS ATLAS 58 prospective randomized placebo 58 seliciclib 58 NATRECOR R 58 microgram kg 58 oral diclofenac 58 CMV disease 58 virological response 58 DLBCL 58 pegylated interferon 58 MGd 58 metastatic malignant melanoma 58 relapsed AML 58 recurrent malignant glioma 58 nonrandomized 58 pharmacodynamic PD 58 #mg BID [003] 58 castration resistant prostate cancer 58 PegIFN RBV 58 peg interferon 58 ponatinib 58 topotecan 58 refractory multiple myeloma 58 alfa 2a 58 adjuvant tamoxifen 58 baminercept 58 Rate ORR 58 multicenter Phase II 58 clinically meaningful improvements 58 HCV genotypes 58 cell lymphoma CTCL 58 5-fluorouracil/leucovorin 58 postoperatively 58 KRAS wild 58 ALT flares 58 NEO3 58 randomized blinded 58 mutated KRAS 58 celgosivir 58 dacarbazine 58 stage IIIb 58 Taxotere ® 58 CANCIDAS 58 CHOP chemotherapy 58 antitumor activity 58 RTOG 58 receiving VICTRELIS 58 zoledronic acid 58 multicentre randomized 58 % CI #.#-#.# [007] 58 lymphopenia 58 metastatic renal cell 58 concurrent chemoradiation 58 rituximab refractory 58 μg doses 58 pharmacokinetic PK 58 FOLFOX6 58 gemcitabine cisplatin 58 cisplatin vinorelbine 58 lymphoma CTCL 58 dose dose escalation 58 LPV r 58 subcutaneous PRO 58 response CCyR 58 events AEs 58 Phase 2a clinical 58 TLUS 58 pharmacodynamic 58 IMC A# 58 adjunctive placebo 58 sUA 58 trabectedin 58 statistically significant improvement 58 rFVIIa 58 darunavir ritonavir 58 splenectomized 58 breast carcinoma 58 VcMP 58 phase IIb 58 differentiated thyroid 58 huC# DM4 58 haematologic 58 randomized multicenter 58 hematologic toxicity 58 F FDG PET 58 sirolimus eluting stent 58 dasatinib Sprycel ® 58 HRPC 58 Randomized Phase II 58 mg m² 58 Pharmacokinetics PK 58 Xanafide 58 ENDEAVOR IV 58 RESIST studies 58 prior relapsers 57 ASCT 57 NLX P# 57 prospective multicenter 57 secondary endpoints 57 BR.# 57 MADRS score 57 PXD# 57 PERSEUS 57 EDSS scores 57 mCi kg 57 adefovir treated 57 ritonavir boosted 57 HIV RNA 57 adefovir 57 multicenter Phase III 57 Scale EDSS 57 peginterferon alfa 2a #KD 57 TACE 57 lenalidomide 57 apremilast 57 lintuzumab 57 dose escalation Phase 57 cilengitide 57 Phase IIa trial 57 anti leukemic 57 oral allopurinol 57 NSABP B 57 fallopian tube cancers 57 cancer mCRC 57 TMC# C# 57 PSADT 57 sorafenib Nexavar ® 57 Phase Ia 57 pT3 57 placebo controlled 57 achieved statistical significance 57 FLT3 ITD 57 adecatumumab 57 ischemic cardiomyopathy 57 Crohn Disease Activity 57 BARACLUDE ® 57 NCCTG N# 57 AP# [003] 57 PREZISTA rtv 57 EDEMA4 trial 57 microbiological eradication 57 HPV-#/# 57 PROMACTA 57 mg kg cohorts 57 FOLOTYN 57 tumor lysis syndrome 57 goserelin 57 daily Infergen 57 carboplatin 57 EMPHASIS HF trial 57 Pegasys ® 57 imetelstat 57 cinacalcet 57 stage IIIb IV 57 active comparator 57 Imprime PGG 57 ILLUMINATE 57 hypercalcemia 57 mg qd 57 KRAS mutations 57 CML CP 57 paclitaxel carboplatin 57 Allovectin 7 ® 57 INCB# [001] 57 enzastaurin 57 tapentadol ER 57 CYT# 57 ara C 57 baseline HbA1c 57 discontinuations due 57 sorafenib 57 vertebral fracture 57 multicenter randomized double 57 double blinded placebo 57 HBeAg 57 bosentan 57 hA# 57 Phase IIIb clinical 57 dose cytarabine 57 stage IIIB IV 57 HER2 negative 57 doxorubicin cyclophosphamide 57 HUMIRA achieved PASI 57 metastatic hormone refractory 57 tipranavir ritonavir 57 prespecified 57 thromboembolic events 57 randomized multicenter trial 57 oral rivaroxaban 57 lopinavir r 57 Phase IIa clinical 57 EGFR TKI 57 dacarbazine chemotherapy 57 multicenter placebo controlled 57 mg kg 57 entecavir 57 cetuximab 57 trastuzumab Herceptin R 57 liposomal doxorubicin 57 median survivals 57 milatuzumab 57 VFEND 57 relapsers 57 bone metastasis 57 corticosteroid dose 57 DEB# 57 renal tumors 57 plus MTX 57 administered subcutaneously 57 metastatic pancreatic 57 lamivudine monotherapy 57 mucosal healing 57 ENDEAVOR II 57 sunitinib malate 57 randomized controlled Phase 57 dose regimens 57 Index CDAI 57 ganetespib 57 prior antiangiogenic therapy 57 Kaplan Meier 57 telaprevir dosing 57 seropositive patients 57 relapsed myeloma 57 doxorubicin docetaxel 57 interferon alfa 57 Cotara 57 PEGylated interferon beta 1a 57 mg BID dose 57 Proxinium TM 57 QTcF 57 QTc prolongation 57 Ph + ALL 57 trastuzumab 57 trials RCTs 57 Enzastaurin 57 multiple myeloma MM 57 azacytidine 57 angiographic outcomes 57 Secondary endpoints included 57 hours postdose 57 undetectable viral load 57 STELARA 57 HBV DNA 57 CYPHER Stent 57 disease progression 57 multicenter randomized placebo controlled 57 EDSS score 57 CLARITY study 57 phase IIa 57 REYATAZ r 57 MACCE 57 % Confidence Interval 57 CALGB 57 intravesical 57 resectable 57 irinotecan chemotherapy 57 oral Hycamtin 56 methotrexate MTX 56 severe exacerbations 56 EGFR mutation positive 56 cytoreduction 56 oxycodone CR 56 TG# [001] 56 refractory CTCL 56 tocilizumab 56 evaluating tivozanib 56 histologies 56 genotype 1a 56 superficial bladder cancer 56 EBRT 56 log# copies mL 56 severe neutropenia 56 Phase 2b trial 56 baseline LDH 56 Engerix B 56 relapsed GBM 56 EFAPROXYN 56 dose dexamethasone 56 INC# 56 bone metastases 56 undetectable hepatitis C 56 virologic responses 56 phase IIb trial 56 HbA1c levels 56 custirsen 56 EVEREST II 56 nonmetastatic 56 relapsed SCLC 56 afatinib 56 posttreatment 56 prospectively stratified 56 Primary endpoints 56 colorectal liver metastases 56 velafermin 56 relapsing multiple sclerosis 56 ELACYT 56 refractory acute myeloid 56 interferon ribavirin 56 cisplatin chemotherapy 56 TIMP 1 56 tamoxifen therapy 56 subanalysis 56 basal cell carcinoma BCC 56 Phase 2b randomized 56 bronchial thermoplasty 56 chronic GVHD 56 OPT CHF 56 primary endpoints 56 HCV viral 56 amrubicin 56 Hepatocellular Carcinoma HCC 56 lymphadenectomy 56 radical nephrectomy 56 bevacizumab 56 advanced adenoma 56 mcg Albuferon 56 mg q#h 56 retrospective cohort 56 OPAXIO 56 GAMMAGARD 56 COPAXONE R 56 pegylated interferon alfa 2a 56 antibody MAb 56 GSK# [001] 56 unblinded 56 biologic therapy 56 demonstrated antitumor activity 56 nitazoxanide 56 efficacy endpoints 56 tumor necrosis 56 Virologic 56 ixabepilone 56 Alocrest 56 YONDELIS 56 Phase 1a 56 ertapenem 56 TNF antagonist 56 androgen suppression 56 Elitek 56 fosbretabulin 56 blinded randomized placebo controlled 56 vinorelbine 56 disease progression TTP 56 noninferiority 56 aflibercept 56 MIRCERA 56 PROSTVAC TM 56 Aflibercept 56 operable breast cancer 56 Navelbine 56 Kaplan Meier estimates 56 icatibant 56 CLORETAZINE TM VNP#M 56 PROSTVAC ® 56 relapsing remitting multiple sclerosis 56 PEG Interferon alfa 56 ibandronate 56 APTIVUS 56 doripenem 56 tumor resection 56 log# 56 recurrent glioblastoma 56 SABCS 56 serum urate 56 copies mL 56 CR# vcMMAE 56 Tumor shrinkage 56 TEAEs 56 xenograft models 56 laboratory abnormalities 56 postmenopausal osteoporotic women 56 Pharmacokinetic parameters 56 transplant ASCT 56 fludarabine 56 alvespimycin 56 ZOLINZA 56 Telintra 56 AVADO 56 metastatic disease 56 adjuvant therapy 56 Vectibix 56 postintervention 56 nonmetastatic prostate cancer 56 YERVOY 56 cisplatin gemcitabine 56 PSMA ADC 56 experienced virologic failure 56 talabostat 56 primary efficacy endpoints 56 T#I [002] 56 blinatumomab 56 DASISION 56 MAGE A3 ASCI 56 Cell Lymphoma 56 Xelox 56 RECORD1 56 boosted protease inhibitor 56 IRX 2 56 Follicular Lymphoma 56 dacetuzumab 56 CDAI 56 metastatic lung cancer 56 CSBM 56 demonstrated statistically significant 56 PSA nadir 56 moderately emetogenic 56 adjuvant radiation 56 pharmacokinetic parameters 56 seroprotection 56 NovoTTF 56 SCH # 56 elevated ALT 56 null responder 56 Phase #/#a 56 Phase IIb trials 56 recurrent glioma 56 taxane resistant 56 erlotinib 56 adjuvant GIST 56 adjuvant cisplatin 56 EchoCRT 56 inflammatory lesions 56 mesalamine granules 56 HAM D# scores 56 Solid Tumours 56 lymph node involvement 56 antiretroviral naive 56 ofatumumab 56 maximally tolerated dose 56 BENICAR HCT 56 antiretroviral naïve 56 efficacy endpoint 56 Secondary efficacy endpoints 56 μmol L 56 genotype 1b 56 COU AA 56 surrogate endpoint 56 receiving golimumab 56 advanced adenomas 56 pancreatic carcinoma 56 pegylated interferon peg IFN 56 randomization 56 SCIg 56 hypogonadal men 56 thymoma 56 HuMax EGFr 56 FOLFIRINOX 56 leukemia CLL 56 CTAP# Capsules 56 hematologic adverse 56 PREZISTA ritonavir 56 HER2 expression 56 fulvestrant 56 morphometric vertebral fractures 56 HGS ETR2 56 Phase III randomized 56 relapsing MS 56 mg/m2 cohort 56 tipranavir 56 anastrozole 56 recurrent VTE 56 mg TID 56 piperacillin tazobactam 56 ACR# ACR# 56 MVax R 56 resected pancreatic cancer 56 underwent CABG 55 ancrod 55 budesonide foam 55 Study GL# 55 tolerability 55 ipsilateral stroke 55 malignant pleural mesothelioma 55 IV melanoma 55 achieving PASI 55 microbiologically evaluable 55 achieve sustained virologic 55 pharmacokinetic PK study 55 BEACOPP 55 medically inoperable 55 EDEMA3 55 receiving INTRON 55 AEGR 55 relapsed CLL 55 dexamethasone 55 SPIRIT FIRST 55 ARB telmisartan 55 GPNMB 55 MAGE A3 55 undergone splenectomy 55 ErbB2 positive 55 EGFR mutations 55 Genasense ® 55 relapsing remitting MS 55 XGEVA 55 Tarceva TM 55 Psoriasis Area 55 ARIKACE 55 Ophena TM 55 anterior uveitis 55 gout flares 55 IU ml 55 mcg linaclotide 55 CVP chemotherapy 55 recurrent GBM patients 55 satraplatin 55 TG MV 55 daunorubicin 55 romiplostim 55 recurrent metastatic 55 univariate analysis 55 Brentuximab Vedotin SGN 55 histologically 55 receptor tyrosine kinase inhibitor 55 sorafenib Nexavar 55 tumor histology 55 FOLFIRI alone 55 completely resected 55 oral deforolimus 55 enoximone 55 eosinophilic asthma 55 Augment Injectable 55 liver histology 55 cGy 55 Phase IIIb 55 Phase 2b clinical 55 chemo radiotherapy 55 pegylated liposomal doxorubicin PLD 55 PS# [001] 55 Cloretazine R VNP#M 55 cytologically confirmed 55 irbesartan 55 chemotherapy docetaxel 55 mcg doses 55 mITT population 55 assessing T DM1 55 eribulin 55 ATACAND 55 Ozarelix 55 bosutinib 55 STRIDE PD 55 iclaprim 55 vidofludimus 55 pulmonary metastases 55 chronic HCV genotype 55 ALND 55 nonvertebral fractures 55 resminostat 55 panitumumab 55 adjuvant chemotherapy 55 trabedersen 55 ADAGIO study 55 MELD scores 55 mitoxantrone plus 55 LVEF 55 ACZ# 55 metastatic malignant 55 tipranavir r 55 relapsed Hodgkin lymphoma 55 CA4P 55 mg m 55 DOXIL 55 ADXS# 55 parathyroidectomy 55 glatiramer acetate 55 docetaxel prednisone 55 PreCISe study 55 plasma HCV RNA 55 romidepsin 55 RSD# oral 55 CYT# potent vascular disrupting 55 double blinded randomized 55 Betaferon ® 55 masked placebo controlled 55 lymph node metastases 55 IFN alfa 55 GEM OS1 55 Virulizin ® 55 pediatric acute lymphoblastic 55 Renal Cell Carcinoma RCC 55 small lymphocytic lymphoma 55 virologic suppression 55 stent thromboses 55 EndoTAG TM -1 55 radiotherapy RT 55 placebo controlled trials 55 virus HCV protease inhibitor 55 AVOREN 55 log# IU mL 55 ER CHOP 55 metastatic lesions